Clinical Study on the Efficacy and Safety of Shenling Baizhu Powder in the Prevention and Treatment of Delayed Diarrhea Caused by Irinotecan

Abstract

Abstract: Objective To investigate the efficacy and safety of Shenling Baizhu powder in the prevention and treatment of delayed diarrhea caused by irinotecan(CPT-11). Methods A total of 60 patients with advanced colorectal cancer in the Department of Gastrointestinal Oncology, Jiangsu Provincial Hospital of Traditional Chinese Medicine between January 2019 and August 2021 were retrospectively selected and divided into an observation group (n=30) and a control group (n=30) according to whether they took traditional Chinese medicine or not. The treatment group started to take Shenling Baizhu Powder orally on the 1st day before chemotherapy, 2 times a day, 1 bag (100 mL) at a time, for 2 consecutive cycles of chemotherapy; the control group was treated with chemotherapy alone. The grade of delayed diarrhea caused by CPT-11, physical condition evaluation (KPS score), immune status (the levels of CD4⁺, CD8⁺ and CD3⁺) and adverse reactions were compared between the two groups. Results Compared with the delayed diarrhea incidence rate of 46.67% (14/30) in the control group, the delayed diarrhea incidence rate of 26.67% (8/30) in the observation group was slightly reduced with no difference (P>0.05). The improvement rate of KPS score of 53.33% (16/30) in the observation group was slightly higher than 40.00% (12/30) in the control group, and there was no difference after comparison (P>0.05). After treatment, the levels of CD4⁺, CD8⁺ and CD3⁺ in the two groups were significantly higher than those before treatment (P<0.05), and the levels of CD4⁺, CD8⁺ and CD3⁺ in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions (myelosuppression, liver and kidney function damage, nausea and vomiting, oral ulcers and loss of appetite) between the two groups (P>0.05). Conclusion Shenling Baizhu Powder can prevent and treat delayed diarrhea caused by irinotecan, it can slightly reduce the incidence of diarrhea, improve physical and immune status, and improve the curative effect with good safety.

Key words: delayed diarrhea, Irinotecan, Shenling Baizhu powder, chemotherapy

CLC Number:

R574.62

LIU Jia-yun, WU Guan-nan, HUAN Xiang-kun, LIU Fu-kun, LIU Shen-lin. Clinical Study on the Efficacy and Safety of Shenling Baizhu Powder in the Prevention and Treatment of Delayed Diarrhea Caused by Irinotecan[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(23): 22-25.

References

[1] Alemany C.Etirinotecanpegol:development of a novel conjugated topoisomerase I inhibitor[J]. Curr Oncol Rep,2014,16(2):367.
[2] 梅丹,陆俊国,顾海娟,等.伊立替康联合替吉奥方案化疗致严重迟发性腹泻1例分析[J].中国药物警戒,2020,17(6):373-376.
[3] Deng C, Lou Y, Gao Y, et al.Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial[J]. Trials,2020,21(1):370.
[4] 林彬. 伊立替康联合卡铂致迟发性腹泻伴骨髓抑制1例的药学监护[J].中国乡村医药,2021,28(3):50-51.
[5] 吴亿晗,成颜芬,王迪,等.葛根芩连汤三氯甲烷提取物缓解伊立替康所致肠毒性的作用机制分析[J].中国实验方剂学杂志,2021, 27(16):16-23.
[6] 田剑波,温艳,杨卓煜,等.全球结直肠癌筛查指南及共识质量评价[J].中华流行病学杂志,2021,42(2):241-247.
[7] Freites-Martinez A, Santana N, Arias-Santiago S, et al.Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies[J]. Actas Dermo-Sifiliográficas,2020,112(1):90-92.
[8] 崔庆丽,胡彦辉,崔庆安,等.人参健脾丸治疗伊立替康所致迟发性腹泻及对肠道菌群和血清炎症因子的影响[J].中医药学报,2021, 49(5):83-86.
[9] 高宇. 基于肠道菌群探讨生姜泻心汤预防伊立替康迟发性腹泻的机制研究[D].北京:北京中医药大学,2021.
[10] Hikino K, Ozeki T, Koido M, et al.Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project[J]. J Hum Genet, 2019,62(12):1195-1202.
[11] 熊笑笑,王骥,马红钦,等.预防性使用奥曲肽对腹腔镜胰十二指肠切除术后并发症的影响分析[J].中国肿瘤临床,2021,48(9):452-457.
[12] 吕阗,李静,赵玉玲,等.中药直肠点滴联合穴位埋线预防及治疗伊立替康引起迟发型腹泻的效果观察[J].中医临床研究,2020,12(15): 129-131.
[13] 葛思堂,左芦根,邱权威,等.直肠癌预防性回肠造口还纳术后早期肠内营养对肠功能康复的影响研究[J].肠外与肠内营养,2022, 29(2):89-92,98.
[14] 邓大一,羌晓华,周勇.艾灸对直肠癌术后低位前切除综合征相关腹泻的疗效观察[J].中国中西医结合外科杂志,2021,27(6):841-845.
[15] 刘译鸿,陈亚栋,马灏川,等.参苓白术散治疗消化系统肿瘤术后腹泻的系统评价和Meta分析[J].中国民间疗法,2022,30(10):62-65.
[16] 钟伟恩,叶红,谭益秋,等.参苓白术颗粒联合西药治疗对抗生素相关性腹泻患儿免疫功能的影响[J].黑龙江医学,2022,46(4):439-441.
[17] 尹平,郭朋璐,宋君宇.美沙拉嗪联合参苓白术散治疗溃疡性结肠炎的效果观察[J].河北医药,2021,43(24):3741-3744.
[18] 华海燕. 针刺联合参苓白术散加减治疗脾虚湿热型溃疡性结肠炎的临床观察[J].广州中医药大学学报,2022,39(3):586-593.
[19] Cho J H.Immunotherapy for Non-small-cell Lung Cancer: Current Status and FutureObstacles[J]. Immune Netw,2017,17(6):378-391.
[20] Kim H, Kwon H J, Han Y B, et al.Increased CD3+ T cells with a low FOXP3+/CD8+ T cellratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients[J]. Mod Pathol,2019,32(3):367-375.